|
|
News Breaks
|
November 2, 2009
|
| 16:00 EDT |  | ARAY |
| theflyonthewall.com: | Accuray sees FY10 revenue in-line with consensus | | Accuray's (ARAY) CEO Euan S. Thomson is optimistic about the growth of the company's main product line, CyberKnife. Since the CyberKnife has moved into extra-cranial radiation treatment from intra-cranial, the product has gained momentum. It is now being used as the preferred treatment for lung, prostate and breast cancer. Thomson sees Europe as the fastest growing market going forward, with other countries emerging from the recession at different rates. He forecasts FY10 revenue of $215M-$230M vs. consensus estimates of $222.88M. These comments were made on the Accuray Investor and Analyst Meeting. :theflyonthewall.com |
|
|
News For ARAY From The Last 14 Days Check below for free stories on ARAY the last two weeks.
There are 2 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 8, 2012
|
| 16:13 EDT |  | ARAY |
| | 16:12 EDT | | ARAY |
|
|
|
|
|
Subscribe for More Information